A detailed history of Sei Investments CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Sei Investments CO holds 12,072 shares of DNLI stock, worth $257,133. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,072
Previous 11,861 1.78%
Holding current value
$257,133
Previous $254,000 2.76%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

BUY
$15.83 - $23.35 $3,340 - $4,926
211 Added 1.78%
12,072 $247,000
Q4 2023

Feb 14, 2024

SELL
$16.2 - $23.18 $6,463 - $9,248
-399 Reduced 3.25%
11,861 $254,000
Q3 2023

Nov 14, 2023

SELL
$20.63 - $30.17 $87,904 - $128,554
-4,261 Reduced 25.79%
12,260 $252,000
Q2 2023

Aug 11, 2023

BUY
$23.37 - $32.96 $3,575 - $5,042
153 Added 0.93%
16,521 $487,000
Q1 2023

May 12, 2023

BUY
$21.91 - $32.67 $80,343 - $119,800
3,667 Added 28.87%
16,368 $377,000
Q4 2022

Feb 10, 2023

SELL
$26.28 - $33.92 $87,170 - $112,512
-3,317 Reduced 20.71%
12,701 $353,000
Q3 2022

Nov 14, 2022

BUY
$25.97 - $38.53 $146,990 - $218,079
5,660 Added 54.64%
16,018 $492,000
Q2 2022

Aug 15, 2022

SELL
$20.88 - $35.19 $3,340 - $5,630
-160 Reduced 1.52%
10,358 $305,000
Q1 2022

May 13, 2022

SELL
$29.0 - $47.27 $24,186 - $39,423
-834 Reduced 7.35%
10,518 $328,000
Q4 2021

Feb 14, 2022

SELL
$42.59 - $55.02 $18,441 - $23,823
-433 Reduced 3.67%
11,352 $498,000
Q3 2021

Nov 12, 2021

BUY
$48.48 - $78.23 $153,875 - $248,302
3,174 Added 36.86%
11,785 $588,000
Q2 2021

Aug 06, 2021

SELL
$50.3 - $78.44 $559,285 - $872,174
-11,119 Reduced 56.36%
8,611 $675,000
Q1 2021

May 12, 2021

BUY
$53.8 - $81.53 $100,283 - $151,971
1,864 Added 10.43%
19,730 $1.43 Million
Q4 2020

Feb 08, 2021

SELL
$36.89 - $93.56 $18,076 - $45,844
-490 Reduced 2.67%
17,866 $1.5 Million
Q3 2020

Nov 06, 2020

BUY
$23.13 - $38.84 $424,574 - $712,947
18,356 New
18,356 $658,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.86B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Sei Investments CO Portfolio

Follow Sei Investments CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sei Investments CO, based on Form 13F filings with the SEC.

News

Stay updated on Sei Investments CO with notifications on news.